Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXEO Lexeo Therapeutics	$4.18 -0.2%	$3.49	$1.45 ▼ $19.50	$139.10M	0.52	535,134 shs	442,159 shs
MGX Metagenomi	$1.59 +1.9%	$1.60	$1.23 ▼ $5.50	$58.31M	-0.33	822,879 shs	639,830 shs
NRSN NeuroSense Therapeutics	$1.98 -10.0%	$1.56	$0.51 ▼ $2.60	$30.07M	1.62	280,327 shs	610,254 shs
QNCX Quince Therapeutics	$1.50 -6.3%	$1.13	$0.51 ▼ $2.45	$72.75M	0.8	303,502 shs	206,275 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXEO Lexeo Therapeutics	-0.24%	-1.42%	+54.81%	+1.95%	-71.45%
MGX Metagenomi	+1.92%	+7.43%	-4.22%	+7.43%	-58.16%
NRSN NeuroSense Therapeutics	-10.00%	-19.18%	+30.26%	+98.99%	+132.50%
QNCX Quince Therapeutics	-6.25%	+10.29%	+47.06%	+11.11%	+113.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXEO Lexeo Therapeutics	2.3877 of 5 stars	3.5	2.0	1.6	2.5	0.6
MGX Metagenomi	2.9274 of 5 stars	3.5	3.0	3.3	1.7	0.6
NRSN NeuroSense Therapeutics	2.5481 of 5 stars	3.5	3.0	3.3	1.7	0.0
QNCX Quince Therapeutics	3.5787 of 5 stars	3.6	5.0	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	297.13% Upside
MGX Metagenomi	3.00	Buy	$13.00	717.61% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	607.07% Upside
QNCX Quince Therapeutics	3.29	Buy	$8.00	433.33% Upside

Current Analyst Ratings Breakdown

Latest NRSN, LXEO, MGX, and QNCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/4/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXEO Lexeo Therapeutics	$650K	213.50	N/A	N/A	$3.53 per share	1.18
MGX Metagenomi	$52.29M	1.14	N/A	N/A	$6.28 per share	0.25
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	$0.19 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	N/A
QNCX Quince Therapeutics	-$56.83M	-$1.39	N/A	N/A	N/A	N/A	-117.52%	-34.22%	8/12/2025 (Estimated)

Latest NRSN, LXEO, MGX, and QNCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
4/7/2025	Q4 2024	NRSN NeuroSense Therapeutics	-$0.12	-$0.06	+$0.06	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXEO Lexeo Therapeutics	0.01	3.42	3.42
MGX Metagenomi	N/A	5.85	5.85
NRSN NeuroSense Therapeutics	N/A	2.21	2.21
QNCX Quince Therapeutics	0.82	4.05	4.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXEO Lexeo Therapeutics	60.67%
MGX Metagenomi	N/A
NRSN NeuroSense Therapeutics	1.04%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
LXEO Lexeo Therapeutics	5.30%
MGX Metagenomi	17.80%
NRSN NeuroSense Therapeutics	27.40%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable
QNCX Quince Therapeutics	60	45.47 million	36.24 million	Optionable

NRSN, LXEO, MGX, and QNCX Headlines

Recent News About These Companies

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from Brokerages

June 26 at 2:10 AM | marketbeat.com

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

June 25 at 4:19 PM | businesswire.com

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

June 18, 2025 | businesswire.com

Quince Therapeutics raises $11.5 million in private placement

June 14, 2025 | investing.com

Quince Therapeutics Raises $11.5M in Private Placement

June 13, 2025 | tipranks.com

Quince Therapeutics' (QNCX) Buy Rating Reaffirmed at D. Boral Capital

June 13, 2025 | marketbeat.com

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

June 12, 2025 | businesswire.com

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

June 3, 2025 | businesswire.com

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025 | seekingalpha.com

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025 | finance.yahoo.com

Quince Therapeutics to Present at Citizens Life Sciences Conference

April 30, 2025 | businesswire.com

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

April 3, 2025 | businesswire.com

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)

March 27, 2025 | markets.businessinsider.com

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

March 24, 2025 | businesswire.com

Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation

March 24, 2025 | msn.com

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

February 7, 2025 | businesswire.com

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025 | businesswire.com

Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

February 4, 2025 | markets.businessinsider.com

Quince Therapeutics secures USPTO nod for A-T treatment patent

February 4, 2025 | msn.com

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

February 4, 2025 | businesswire.com

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

January 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, LXEO, MGX, and QNCX Company Descriptions

Lexeo Therapeutics NASDAQ:LXEO

$4.18 -0.01 (-0.24%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.19 +0.01 (+0.24%)

As of 06/26/2025 07:19 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Metagenomi NASDAQ:MGX

$1.59 +0.03 (+1.92%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.61 +0.02 (+1.26%)

As of 06/26/2025 07:38 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

NeuroSense Therapeutics NASDAQ:NRSN

$1.98 -0.22 (-10.00%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.00 +0.02 (+1.06%)

As of 06/26/2025 08:00 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Quince Therapeutics NASDAQ:QNCX

$1.50 -0.10 (-6.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.50 0.00 (0.00%)

As of 06/26/2025 07:21 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time